India, March 16 -- Dyne Therapeutics Inc. (DYN) announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg Q4W (approximate PMO dose). The trial is evaluating DYNE-251 in individuals with Duchenne muscular dystrophy or DMD who are amenable to exon 51 skipping.
The company will present updated results from the trial this week at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
The updated assessment of the DELIVER trial evaluating DYNE-251 includes new functional data out to 12 months from 6 patients enrolled in the 20 mg/kg Q4W cohort, and 18-month functional data from 6 pa...